Access Blood Flow Surveillance in Native Arteriovenous Fistula: Reduction in Thrombosis Rate and Improvement in Assisted and Secondary Patency. A Randomized Clinical Trial

Ines Aragoncillo, <sup>1</sup> Soraya Abad,<sup>1</sup> Silvia Caldés,<sup>2</sup> Antonio Cirugeda,<sup>2</sup> Almudena Vega,<sup>1</sup> Cristina Fernandez,<sup>4</sup> Cristina Moratilla,<sup>3</sup> Nicolás Macías,<sup>1</sup> Juan Manuel Lopez Gomez,<sup>1</sup> Fernando De Alvaro Moreno.<sup>2</sup>

<sup>1</sup> Nephrology, H Gregorio Marañon, Madrid, Spain; <sup>2</sup> Nephrology, H Infanta Sofia, Madrid, Spain; <sup>3</sup> Nephrology, Clinica Fuensanta, Madrid, Spain; <sup>4</sup> Nephrology, H Clinico, Madrid, Spain.

## **Background:**

Stenosis is the main cause of arteriovenous fistula (AVF) failure. It is still unclear if surveillance based on Vascular Access Blood Flow (QA) enhances AVF function and longevity.

## **Methods:**

3-year follow up randomized, controlled, multicentric, open-label trial, comparing QA surveillance (pre-emptive repair of subclinical stenoses with angioplasty and/or open surgery) with standard monitoring/surveillance (intervention based on classic criteria) in mature autologous AVFs. AVFs were randomized to either control group (surveillance based on venous pressure, recirculation, dialysis dose...; n=104) or to QA group [QA was measured quarterly using doppler ultrasound (M-Turbo®)and ultrasound dilution method (Transonic®)n=103]. The criteria for intervention in QA group were 25% reduction in QA, QA <500 ml/min or significant stenosis with >50% reduction in vessel lumen and haemodynamic repercussion [Peak Sistolic Velocity (PSV) >400ml/min or PSV stenosis/PSV pre-stenosis > 3).

## **Results:**

Significant reduction in thrombosis rate (0,025 thrombosis/patient/year in the QA group compared with 0,086 thrombosis/patient/year in control group. p= 0,007) Significant improvement in assisted primary patency rate and secondary patency rate in QA group (HR 0,30 CI 0,11-0,82. P=0,011 / HR 0,49 CI 0,26-0,93. p=0,030) No differences in non-assisted primary patency rate between groups (HR 0,98 CI 0,57-1,61. p=0,935). Higher needs of central venous catether and hospitalizations related with VA in control group (p<0,001 / p=0,003). - Higher total VA related costs in control group (217.845  $\in$  vs 124.186  $\in$ . p=0,029).

## **Conclusions:**

QA based surveillance combining doppler ultrasound and ultrasound dilution method prevents thrombosis, increases assisted and secondary patency rate in AVF and it is cost effective.